This information is about nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which is an uncommon type of Hodgkin lymphoma.
On this page
This information is about nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which is an uncommon type of Hodgkin lymphoma.
- What is NLPHL? (page 1)
- Who gets NLPHL and why? (page 2)
- What are the symptoms of NLPHL? (page 2)
- Tests for NLPHL (page 2)
- What are the stages of NLPHL? (page 3)
- The outlook if you have NLPHL (page 4)
- How is NLPHL treated? (page 4)
- What are the treatment side effects? (page 7)
- Follow-up after treatment (page 9)
- What happens if NLPHL comes back? (page 9)
- Newer treatments for NLPHL (page10).
Nodular lymphocyte-predominant Hodgkin lymphoma is an uncommon type of Hodgkin lymphoma – a type of cancer that starts in the lymphatic system. The lymphatic system is part of the immune system. It is a network of glands (lymph nodes) and tubes that carry a fluid called lymph around the body.
Lymphomas develop when white blood cells called lymphocytes become abnormal. The lymphocytes start to grow out of control.They collect in large numbers in lymph nodes and make them swell (enlarge).
About 1 in 20 Hodgkin lymphomas diagnosed (5%) are NLPHL. That means that there are about 90 cases diagnosed in the UK each year.
It is called ‘nodular lymphocyte-predominant’ because it has particular cells that can be seen under a microscope. These are called LP cells (for ‘lymphocyte-predominant’), but doctors sometimes call them popcorn cells because they look a bit like pieces of popcorn.
NLPHL is different to other types of Hodgkin lymphoma. It tends to grow more slowly and to be diagnosed earlier, when it is only growing in one or two groups of lymph nodes. The lymph nodes it grows in tend to be in places that can be easily felt, rather than deep inside the body. For these reasons, treatment is usually very successful and many people are cured.
The two main groups that get NLPHL are children and people in their 30s and 40s. Three out of four cases are diagnosed in males. It is more common in children under 10 than in 10–18 year olds.
We don’t know why some people get NLPHL. You can’t catch it, or pass it on to anyone else. There are no particular risk factors that we know of, so it isn’t down to anything you’ve done or not done.
Lymphomas are not normally inherited. But unlike other types of Hodgkin lymphoma, brothers, sisters and parents of someone with NLPHL have a very slightly higher risk of getting it themselves – but it is still very unlikely.
The only symptom that most people have with NLPHL is enlarged (swollen) lymph nodes. These tend to grow quite slowly and are not usually painful. In most cases, the enlarged lymph nodes are only in one area of the body.
Some people with lymphoma have other symptoms such as weight loss, sweating at night and a high temperature (fever) that comes and goes. These are called B symptoms. They can happen with NLPHL, but only in a small number of cases – about 1 in 6 at most.
Like all lymphomas, the best way to get a diagnosis is for your doctor to take a sample of cells from an enlarged lymph node and examine them under a microscope. This means having a small operation, called a biopsy. Depending on where the affected lymph nodes are, you either have this done under a local or general anaesthetic.
Special tests will also be done on the cells to look for particular proteins that are commonly found on the surface of lymphoma cells. It may take a while to have all the necessary tests done on your biopsy. The sample will be sent to a specialised laboratory where doctors who are experienced in diagnosing lymphoma can examine it.
- check your blood cell counts and make sure you’re not anaemic
- make sure your kidneys and liver are working well
- rule out infections that could flare up when you have treatment, such as hepatitis.
You are most likely to have a CT scan. This is to look for any signs of lymphoma in internal lymph nodes and body organs such as your liver and spleen. Or you may have an MRI scan. This uses magnetism instead of X-rays and may be used in children because it does not involve any radiation.
PET scans are sometimes used to diagnose lymphoma. They are useful because they can help tell the difference between active lymphoma and scar tissue. So they can help doctors to say whether enlarged lymph nodes deep in the body contain lymphoma cells without needing to remove them.
You usually have all these tests done as an outpatient. It will take a few weeks to get all the results back. Understandably, this can be a worrying time, but it is important for your doctor to gather all of this information in order to plan the best treatment for you.
We have more information about the tests and scans mentioned above, which you can read on our website (www.lymphomas.org.uk). You can also print this information at home, or if you prefer, our helpline can send you copies – email firstname.lastname@example.org or ring 0808 808 5555.
Once your doctor has all your test results, they will be able to tell you the ‘stage’ of your lymphoma. This means how far it has grown and spread. Staging is important because it helps your doctor to choose the right treatment for you.
There are four stages. Doctors use Roman numerals for these:
- Stage I means there is lymphoma in only one group of lymph nodes in your body.
- Stage II means there is lymphoma in more than one group of lymph nodes and these are all on the same side of your diaphragm – the sheet of muscle under your ribs.
- Stage III means there is lymphoma in more than one group of lymph nodes and they are on both sides of the diaphragm.
- Stage IV means there is lymphoma in body organs and not just in lymph nodes or your spleen.
About 1 in 10 people diagnosed (10%) also have a ‘B’ after their stage – IB, IIB and so on. This means they have the extra symptoms known as B symptoms – fevers, night sweats and weight loss.
Around 3 out of 4 cases of NLPHL (75%) are stage I or II when they are diagnosed. This is called early stage disease.
Stage III and IV NLPHL is called advanced disease. About 1 in 4 people (25%) have advanced NLPHL when they are diagnosed. Try not to worry if you are one of these people. The main difference is that you will have treatment to your whole body rather than treatment to one area only. Advanced NLPHL still responds very well to treatment.
We have more information about staging on our website (www.lymphomas.org.uk). You can print this information at home, or if you prefer, our helpline can send you copies – email email@example.com or ring 0808 808 5555.
The outlook for NLPHL is generally very good. This is partly because it tends to be at an earlier stage when it is diagnosed and also because it grows very slowly. It tends to respond very well to treatment and most people are either cured or have a long time with no sign of the disease (known as a remission). Although NLPHL can come back (relapse), treatment is often successful and patients can be cured or have another long remission.
It is hard to give exact figures for cure rates – there is less data to go on than for other types of cancer. Statistics are also very general. They apply to a group of people and not any one person in particular.
The best person to talk to about the likely outcome of your treatment is your own lymphoma specialist. While they won’t be able to give you any guarantees ahead of time, they will have access to all your test results and treatment plan so will be able to give you a more informed opinion.
Like other types of lymphoma, the treatment you have depends on:
- how far the disease has grown – the stage of your disease
- the size of your lymph nodes
- whether you have B symptoms – weight loss, night sweats and fevers
- your age, fitness and general health
- your feelings about treatment and issues that may be important to you in the future, such as having children.
Your doctor will also think about the long-term effects of any treatment you have. This is important because treatment for NLPHL is very successful so most patients live for many years, even if the lymphoma comes back.
Through research, treatment for many people with NLPHL has become less intensive than it used to be. Doctors and researchers continue to try and find treatments that have as few side effects as possible, particularly long-term side effects. These are rare, but for a small number of people, they can cause more health problems than the lymphoma itself, especially when the lymphoma is very slow-growing.
Early stage disease without B symptoms
If you have early stage NLPHL you are most likely to have one of the following:
- surgery to remove your lymph nodes
- surgery followed by radiotherapy.
It is most usual to have the all the lymph nodes containing lymphoma removed and then to have radiotherapy to the area. The type of surgery, time you spend in hospital and time it takes to recover from your surgery will depend on where in the body the lymph nodes are and how many you need to have taken out.
There has been some research looking into having only surgery and then watching closely for any signs that the lymphoma has come back. This is called ‘watch and wait’. It means that you avoid the side effects of radiotherapy.
You can only have ‘watch and wait’ if there are no signs of lymphoma after your surgery. There is a chance that the lymphoma will come back in the future (relapse), but then you can have more treatment and this is nearly always successful. Some research has been done to show that there is no difference in survival rates in children who had watch and wait compared to those who had radiotherapy after their surgery.
You usually have radiotherapy over three to four weeks. You have a small dose daily, from Monday to Friday each week. Having treatment is similar to having an X-ray. It doesn’t hurt and only takes a few minutes.
We have more information about radiotherapy for lymphoma and about the ‘watch and wait’ approach, which you can read on our website (www.lymphomas.org.uk). You can also print this information at home, or if you prefer, our helpline can send you copies – email firstname.lastname@example.org or ring 0808 808 5555.
Early stage disease with B symptoms
If you have early stage NLPHL with B symptoms (fevers, night sweats and weight loss), you may need more intensive treatment. Doctors generally recommend that you have treatment with a combination of chemotherapy drugs. This is the same as the treatment they give for stage III and IV NLPHL, which is outlined below.
Advanced stage disease
If you have advanced-stage (stage III or IV) NLPHL but are well, you may have ‘watch and wait’.
If you have symptoms, you are most likely to have treatment with a combination of chemotherapy drugs. You may have:
ABVD or R-ABVD
CVP or R-CVP
The R in each of these combinations stands for rituximab. This is an immunotherapy drug called a monoclonal antibody. These target particular proteins on the surface of cancer cells. Rituximab targets CD20, which is found on the surface of NLPHL cells. The antibody sticks to all the CD20 protein it finds, which marks them out for the immune system to then find and kill them.
R-CHOP stands for:
R – rituximab
C – cyclophosphamide
H – doxorubicin (also called hydroxydaunorubicin or doxorubicin hydrochloride)
O – vincristine (also called Oncovin®)
P – prednisolone
Cyclophosphamide, doxorubicin and vincristine are all chemotherapy drugs. Prednisolone is a steroid tablet.
You have prednisolone as a tablet. All the other drugs you have through a drip into a vein (intravenously). You usually have this treatment in several cycles, each lasting three weeks. You have the rituximab and chemotherapy on the first day of each cycle. You take prednisolone tablets for the next five days and then you have a break with no treatment for just over two weeks.
Three weeks after your treatment started, the second cycle begins and you have chemotherapy and rituximab injections again. For NLPHL, you usually have six cycles, so the treatment lasts for about 18 weeks in total.
CVP is a chemotherapy combination often used for children with NLPHL. It stands for:
C – cyclophosphamide
V – vincristine
P – prednisolone
You have this treatment in three-weekly cycles. You have cyclophosphamide and vincristine on the first day of each cycle as a drip into a vein (intravenously). You then take prednisolone tablets for the next five days. After a break for just over two weeks, the cycle begins again.
You may have CVP along with rituximab. This is called R-CVP.
ABVD is another chemotherapy combination you may have for NLPHL. It stands for:
A – doxorubicin (Adriamycin)
B – bleomycin
V – vinblastine
D – dacarbazine
All these drugs are chemotherapy drugs that you have through a drip into a vein (intravenously). You usually have several cycles of treatment, each lasting four weeks. You have all the drugs together twice in each cycle, on the first day and the 15th day.
ABVD is used less often on its own these days. But you may have it along with rituximab, which is called R-ABVD.
People who are not well enough to have chemotherapy might have rituximab on its own.
All medical treatment has potential side effects. How many you have, which ones and how serious they are varies a lot from person to person. It isn’t possible to tell beforehand exactly how treatment will affect you. The side effects of cancer treatment are mostly temporary and will gradually disappear after your course of treatment is over.
If you have side effects from your treatment, do tell your doctor or specialist nurse. There are medicines they can give you to help with sickness, diarrhoea and other side effects. And they will almost certainly be able to offer advice to help you cope.
You may feel more and more tired as your treatment course goes on. The skin in the treatment area may become a bit red, similar to mild sunburn. Other side effects will depend on which part of your body is being treated. Treatment to your neck may cause a sore throat. Treatment to the stomach area may make you feel sick. Your doctor, specialist nurse or radiographer will explain all the possible side effects before you start treatment.
Chemotherapy and immunotherapy
The side effects you have will depend on:
- the specific drugs you have
- how you tend to react to drugs generally
- how many times you’ve had the drugs before
- other drugs you are having
- your general health.
The most common side effects with R-CHOP and ABVD are:
- An increased risk of picking up an infection
- Feeling or being sick
- Tiredness (fatigue)
- Hair loss or thinning
- Nerve problems (peripheral neuropathy), causing numbness and tingling in your fingers and toes, or abdominal cramps and constipation.
There are quite a few other possible side effects of this treatment and your doctor or chemotherapy nurse will give you written information about them before you start treatment. You won’t have every side effect, but you will almost certainly have some. Everyone’s experience is different.
This means side effects that crop up months or years after you’ve finished your treatment. Fewer people get long-term side effects from NPLHL treatment these days. The treatment has been streamlined over the past few years. As treatment for NPLHL is so successful, doctors have concentrated research on trying to cut down the risk of other medical problems caused by treatment years later. The main potential long-term problems are:
- heart problems
- second cancers.
Some chemotherapy drugs and radiotherapy to the area between your hipbones (the pelvis) can cause problems getting pregnant or fathering a child later on. Most people having treatment for NLPHL will not be at risk of infertility. If you haven’t yet had a family, your specialist will try to choose treatments that won’t harm your fertility. If this isn’t possible, your doctor will talk to you before you start treatment about sperm banking if you’re male, or embryo freezing if you’re female. If embryo freezing isn’t possible, you may be able to have eggs frozen, but this is still experimental at the moment.
Some chemotherapy drugs and radiotherapy to the centre of the chest may increase your risk of heart problems in the future. Your doctor will try and reduce your treatment doses as much as possible to minimise the risk. But you may need to have regular heart checks-ups. You can help yourself by not smoking, keeping to a healthy weight and taking regular exercise.
Your risk of getting another type of cancer in the future may be higher after treatment for NLPHL, although the risk is much lower than it used to be. Radiotherapy is more targeted these days and so normal body tissues receive a lower dose of radiation. This helps to reduce the risk. Your doctor will look for any signs of another cancer during your check-ups for many years after your treatment.
We have more information about late effects on our website (www.lymphomas.org.uk). You can print this information at home, or if you prefer, our helpline can send you copies – email email@example.com or ring 0808 808 5555.
You will have regular check-ups with your specialist after you finish your treatment. At first, these will be every three months or so. But if all is well, they will gradually become less frequent.
At your appointments, your doctor will examine you and ask if anything is troubling you. You may have occasional tests or scans, but generally these are not necessary if you don’t have any symptoms.
Many people find check-ups quite worrying. You may be getting on with life and putting your illness behind you. Having to go back to the hospital can bring back the upset of being diagnosed and treated. But after you’ve been to your appointment, you might feel relieved that your doctor has had an opportunity to make sure all is well.
Unfortunately, NLPHL can sometimes come back (relapse). This may be many years after you were first treated and is one reason why it is so important to keep your follow-up appointments. Fortunately NLPHL usually responds just as well to treatment as it did the first time round and many people will be cured.
NLPHL usually comes back in the same place and rarely becomes more widespread. Your doctor will want to take another biopsy before deciding on treatment.
It is important to check the lymphoma type again because, in very rare cases, NLPHL can come back as a type of fast growing non-Hodgkin lymphoma. Doctors call this ‘transformation’. In one study of 95 patients, NLPHL transformed in around 1 in 6 people. In another study, it transformed in around 1 in 12 people.
If your NLPHL comes back, you may have:
Your doctor will decide on your treatment by taking into account:
- the treatment you had before and how well you coped with it
- how long it was before your NLPHL came back
- the result of your biopsy and tests (the type and stage of the lymphoma that has come back)
- your age, fitness and general health.
You are bound to be upset that your lymphoma has come back. But do remember that it can often be treated successfully. You are likely to get back into remission and may well be cured.
We have more information on our website (www.lymphomas.org.uk) about about the treatment types mentioned on this information sheet and about transformation of lymphoma. You can print this information at home or if you prefer, our helpline can send you copies – email firstname.lastname@example.org or ring 0808 808 5555.
NLPHL treatment is often very successful. Doctors continue to try and find treatments that can still cure the lymphoma but cause fewer side effects, particularly long-term side effects.
One trial is looking at children and young people with NLPHL to see if they can have surgery alone after the diseased lymph nodes have been completely removed. Children who can’t have all their lymphoma removed have two-weekly chemotherapy with cyclophosphamide, vinblastine and steroid tablets (prednisolone).
Other clinical trials are looking at treatment for NLPHL that has come back (relapsed) or hasn’t responded very well to treatment. Drugs being investigated include:
- a monoclonal antibody called ofatumumab
- the biological therapy drugs panobinostat and lenolidomide
- the chemotherapy drugs gemcitabine and bendamustine.
It is too early to say whether any of these treatments will work for NLPHL or whether they will work better than the treatments doctors already use. Your doctors may offer you the chance to take part in a clinical trial, if there is one suitable for you.
We have more information about research and clinical trials, which you can read on our website (www.lymphomas.org.uk). You can also print this information at home or if you prefer, our helpline can send you a copy – email email@example.com or ring 0808 808 5555.
These are a few of the sources we used to prepare this information. The full list of sources is available on request. Please contact us by email (firstname.lastname@example.org) or by ringing 01296 619409 if you would like a copy.
Advani R, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of Clinical Oncology, 2014, 32: 912-918. Available at: www.ncbi.nlm.nih.gov/pubmed/24516013 (Accessed May 2015)
Gorde-Grosjean S, et al. Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology and management. Cancer Bulletin, 2014, 101: 881-890. Available at: www.ncbi.nlm.nih.gov/pubmed/25296072 (Accessed May 2015)
Fanale M. Lymphocyte-Predominant Hodgkin lymphoma: what is the optimal treatment? American Society of Haematology Education Programme, 2013, 406-413. Available at: www.ncbi.nlm.nih.gov/pubmed/24319212 (Accessed May 2015)
Mauz-Körholz C, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Cancer. 2007, 110:179-185. Available at: www.ncbi.nlm.nih.gov/pubmed/17526010 (Accessed May 2015)
Diehl V, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. Journal of Clinical Oncology. 1999,17:776-783. Available at: www.ncbi.nlm.nih.gov/pubmed/10071266 (Accessed May 2015)
With thanks to Professor Peter Johnson, Professor of Medical Oncology at Southampton General Hospital for his help in reviewing this information.
We would also like to thank our reader panel who have given their time to review this information.
We are also grateful to Simon Burns for his donation to help fund this information.
Content last reviewed: June 2015
Content updated: June 2016
Next planned review: June 2018